| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4de36eaaa471d491a1c3f2ae25eaef97 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2503-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-948 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0693
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23J1-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23J3-343 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23J3-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23J1-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L1-305 |
| filingDate |
2000-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2db85c4edac90a73d94e6053be14c58b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c1817d8c3c334c21157a719c5e6a011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27336460868b51ad9256590863cee348
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac707ab5c0ebeea2a7656160f0a1c06e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92ac257e3c02d22c61505eef3903e1b3 |
| publicationDate |
2002-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1235585-A2 |
| titleOfInvention |
Use of a milk protein hydrolysate in the treatment of diabetes |
| abstract |
Use of a milk protein hydrolysate which is preferably a whey protein hydrolysate or caseinoglycomacropeptide (CGMP) in a bioavailable form in the manufacture of a composition for the treatment or prevention of diabetes or syndrome X and a method of treatment or prevention of diabetes or syndrome X are described. The present invention also relates to a method for assessing proglucagon gene expression and GLP-1 release by a cell line derived from an adenocarcinoma of human caecum. |
| priorityDate |
1999-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |